ArticlePloS one2009
New genomic structure for prostate cancer specific gene PCA3 within BMCC1: implications for prostate cancer detection and progression.
Article in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 90 citations in OpenAlex.
- Evaluation of prostate cancer antigen 3 for detecting prostate cancer: a systematic review and meta-analysis.Scientific reports · 2016Pooled it
- CRISPR-Cas9 genome and long non-coding RNAs as a novel diagnostic index for prostate cancer therapy via liposomal-coated compounds.PloS one · 2024Article
- Rho GTPase activating protein 21-mediated regulation of prostate cancer associated 3 gene in prostate cancer cell.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2024Article
- Article
- PRUNE2 inhibits progression of colorectal cancerExperimental and therapeutic medicine · 2022Article
- An Overview of the Role of Long Non-Coding RNAs in Human Choriocarcinoma.International journal of molecular sciences · 2021Review
- PCA3 in Prostate Cancer.Methods in molecular biology (Clifton, N.J.) · 2021Article
- Long non-coding RNAs in prostate tumorigenesis and therapy (Review).Molecular and clinical oncology · 2020Review
- The long non-coding RNAOncotarget · 2019Article
- The use of long non-coding RNAs as prognostic biomarkers and therapeutic targets in prostate cancer.Oncotarget · 2018Review
- Emerging biomarkers in the diagnosis of prostate cancer.Pharmacogenomics and personalized medicine · 2018Review
- Somatic Mutation Analyses in Studies of the Clonal Evolution and Diagnostic Targets of Prostate Cancer.Current genomics · 2017Review
- KLRC3, a Natural Killer receptor gene, is a key factor involved in glioblastoma tumourigenesis and aggressiveness.Journal of cellular and molecular medicine · 2017Article
- Evaluation of a short RNA within Prostate Cancer Gene 3 in the predictive role for future cancer using non-malignant prostate biopsies.PloS one · 2017Article
- Prostate-based biofluids for the detection of prostate cancer: A comparative study of the diagnostic performance of cell-sourced RNA biomarkers.Prostate international · 2016Article
- PCA3 long noncoding RNA modulates the expression of key cancer-related genes in LNCaP prostate cancer cells.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- LncRNA2Function: a comprehensive resource for functional investigation of human lncRNAs based on RNA-seq data.BMC genomics · 2015Article
- Molecular function and regulation of long non-coding RNAs: paradigms with potential roles in cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Review
- Function of PCA3 in prostate tissue and clinical research progress on developing a PCA3 score.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 2 countries.
Funding
Abstract
backgroundThe prostate cancer antigen 3 (PCA3/DD3) gene is a highly specific biomarker upregulated in prostate cancer (PCa). In order to understand the importance of PCA3 in PCa we investigated the organization and evolution of the PCA3 gene locus. METHODS/PRINCIPAL
findingsWe have employed cDNA synthesis, RTPCR and DNA sequencing to identify 4 new transcription start sites, 4 polyadenylation sites and 2 new differentially spliced exons in an extended form of PCA3. Primers designed from these novel PCA3 exons greatly improve RT-PCR based discrimination between PCa, PCa metastases and BPH specimens. Comparative genomic analyses demonstrated that PCA3 has only recently evolved in an anti-sense orientation within a second gene, BMCC1/PRUNE2. BMCC1 has been shown previously to interact with RhoA and RhoC, determinants of cellular transformation and metastasis, respectively. Using RT-PCR we demonstrated that the longer BMCC1-1 isoform - like PCA3 - is upregulated in PCa tissues and metastases and in PCa cell lines. Furthermore PCA3 and BMCC1-1 levels are responsive to dihydrotestosterone treatment. CONCLUSIONS/SIGNIFICANCE: Upregulation of two new PCA3 isoforms in PCa tissues improves discrimination between PCa and BPH. The functional relevance of this specificity is now of particular interest given PCA3's overlapping association with a second gene BMCC1, a regulator of Rho signalling. Upregulation of PCA3 and BMCC1 in PCa has potential for improved diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.